Photo by impulsq from unsplash
Biosimilars are here to stay, but whether they will enjoy widespread uptake remains to be seen. The FDA sets a high bar for approval of biosimilar products, yet many clinicians… Click to show full abstract
Biosimilars are here to stay, but whether they will enjoy widespread uptake remains to be seen. The FDA sets a high bar for approval of biosimilar products, yet many clinicians remain skeptical about the efficacy and safety of these agents. Favorable experience with >30 biosimilars in Europe provides some reassurance that these agents are safe and effective and can be substituted for the reference product.
Keywords:
factors anemia;
biosimilar approvals;
myeloid growth;
growth factors;
new biosimilar;
approvals myeloid
Journal Title: Journal of the National Comprehensive Cancer Network : JNCCN
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the National Comprehensive Cancer Network : JNCCN
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!